JPMorgan Chase & Co. Has $61,000 Stock Position in MediWound Ltd. (NASDAQ:MDWD)

JPMorgan Chase & Co. lowered its holdings in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 95.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,401 shares of the biopharmaceutical company's stock after selling 75,360 shares during the period. JPMorgan Chase & Co.'s holdings in MediWound were worth $61,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in MDWD. MetLife Investment Management LLC bought a new stake in shares of MediWound during the 3rd quarter worth $89,000. Barclays PLC increased its holdings in MediWound by 311.3% in the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company's stock worth $202,000 after purchasing an additional 8,449 shares in the last quarter. Point72 Asset Management L.P. bought a new position in MediWound in the third quarter valued at about $212,000. State Street Corp boosted its stake in shares of MediWound by 219.6% during the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company's stock valued at $1,197,000 after purchasing an additional 45,529 shares in the last quarter. Finally, ARK Investment Management LLC bought a new stake in shares of MediWound during the third quarter worth about $1,806,000. 46.83% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "buy" rating and set a $25.00 target price on shares of MediWound in a research report on Friday, January 10th.

MediWound Stock Down 7.0 %

MDWD traded down $1.37 during midday trading on Friday, hitting $18.13. 65,203 shares of the company were exchanged, compared to its average volume of 78,084. The firm's 50 day moving average price is $18.06 and its 200-day moving average price is $17.78. MediWound Ltd. has a 1-year low of $11.90 and a 1-year high of $24.00. The firm has a market capitalization of $195.62 million, a P/E ratio of -6.25 and a beta of 0.81.

MediWound (NASDAQ:MDWD - Get Free Report) last posted its quarterly earnings data on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period last year, the business earned ($0.24) earnings per share. On average, sell-side analysts predict that MediWound Ltd. will post -2.66 earnings per share for the current fiscal year.

MediWound Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.